Want to see AVD full AI Analyst Report?
American Vanguard (AVD) AI Stock Analysis
Top Page
American Vanguard
(NYSE:AVD)
Weak financial performance and bearish technical indicators are the primary factors weighing on the score, partially mitigated by constructive earnings guidance and strategic initiatives.
American Vanguard (AVD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $32.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 366.69K
- Price to Earnings (P/E)
- -0.6
- Beta (1Y)
- 1.59
- Revenue Growth
- -3.54%
- EPS Growth
- 56.67%
- Country
- US
- Employees
- 739
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Agricultural Inputs
American Vanguard Business Overview & Revenue Model
Company Description
American Vanguard Corporation, through its various subsidiaries, develops, manufactures, and markets a diverse portfolio of specialized chemicals for agricultural, commercial, and consumer applications across the United States and internationally. Th...
How the Company Makes Money
American Vanguard primarily makes money by selling pest-control and crop protection chemicals and related solutions, with revenue recognized from product shipments to customers through multiple go-to-market channels. Key revenue streams include: (1)...
American Vanguard Earnings Call Summary
The call presents a mixed picture: significant operational progress (H1 gross margin improvement, >20% YTD adjusted EBITDA growth, specialty segment strength, R&D investment and announced cost savings) and clear strategic targets for 2026–2028. However, Q2 was notably weaker with a meaningful revenue decline, a steep drop in quarterly adjusted EBITDA, freight-driven margin headwinds, international softness, lower cash and higher net debt. Management emphasizes control of costs, pricing actions, and near-term initiatives to improve operating leverage and expects full-year targets to be met, which tempers the near-term negatives.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated 2026 guidance of $44–$48 million of adjusted EBITDA on $530–$550 million of sales, and said it expects to reach an annualized run rate north of $600 million by the back half of 2028 (about 20% above 2025) with a goal of double‑digit EBITDA margins; near‑term actions include LA plant rationalization to save at least $4 million annualized and pricing to recover freight headwinds (~$2.2M, ~90 bps YTD). Key reported metrics: Q2 sales $117M (vs. $129M a year ago), H1 sales $240M (down ~2% YoY), Q2 adjusted EBITDA $0.6M (vs. $11M prior) while H1 adjusted EBITDA rose to $17M (+>20% YoY), H1 gross margin improved 100 bps to 30% (Q2 GM 30% vs. 31% prior). Business mix and geography: US sales +6% H1 (US crop +5% H1, specialty +10% H1; specialty +11% in Q2), international sales -18% in Q2 and -13% H1; inventories $181M (vs. $191M prior year), cash $43.9M quarter‑end, total debt ~$267.6M and net debt ~$224.7M, and R&D investment up 12% YoY with a target of 50 new product launches over five years to drive $100M of annualized revenue by 2030.
American Vanguard Financial Statement Overview
Summary
Declining revenues, net losses, and negative cash flows indicate weak financial performance, though reduced debt levels offer limited stability.
Income Statement
25NegativeBalance Sheet
45NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 510.32M | 515.11M | 547.31M | 579.37M | 609.62M | 557.68M |
| Gross Profit | 149.95M | 147.56M | 120.32M | 179.16M | 241.35M | 170.72M |
| EBITDA | -10.99M | -11.79M | -9.66M | 44.72M | 62.22M | 57.00M |
| Net Income | -54.58M | -49.88M | -126.34M | 7.52M | 27.40M | 18.59M |
Balance Sheet | ||||||
| Total Assets | 635.34M | 596.54M | 636.72M | 767.55M | 726.31M | 694.16M |
| Cash, Cash Equivalents and Short-Term Investments | 43.90M | 12.43M | 12.51M | 11.42M | 20.33M | 16.29M |
| Total Debt | 284.12M | 191.39M | 167.81M | 162.09M | 76.25M | 78.08M |
| Total Liabilities | 453.96M | 404.14M | 403.61M | 397.54M | 356.33M | 321.42M |
| Stockholders Equity | 181.39M | 192.40M | 233.11M | 370.01M | 369.98M | 372.74M |
Cash Flow | ||||||
| Free Cash Flow | -47.11M | -25.27M | -3.77M | -70.81M | 42.55M | 76.32M |
| Operating Cash Flow | -41.81M | -21.19M | 3.92M | -58.75M | 57.10M | 86.36M |
| Investing Cash Flow | -4.97M | -3.61M | -6.62M | -17.02M | -14.47M | -20.04M |
| Financing Cash Flow | 76.60M | 23.70M | 4.54M | 66.74M | -38.26M | -65.87M |
American Vanguard Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVD, the sentiment is Negative. The current price of 1.10 is below the 20-day moving average (MA) of 1.27, below the 50-day MA of 1.78, and below the 200-day MA of 2.87, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 27.95 is Positive, neither overbought nor oversold. The STOCH value of 51.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVD.
American Vanguard Risk Analysis
American Vanguard disclosed 28 risk factors in its most recent earnings report. American Vanguard reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksAmerican Vanguard Peers Comparison
Overall Rating
UAN75Outperform
IPI68Neutral
BHST52Neutral- AVD43Neutral
BIOX34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| UAN | 75Outperform | $1.34B | 8.36 | 51.56% | 11.42% | 17.47% | 82.16% |
| IPI | 68Neutral | $424.96M | 15.81 | 5.27% | ― | 4.20% | ― |
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| BHST | 52Neutral | $37.63M | -3.07 | -58.30% | ― | 17.50% | 24.63% |
| AVD | 43Neutral | $32.45M | -0.58 | -27.83% | ― | -3.54% | 56.67% |
| BIOX | 34Underperform | $13.15M | -0.06 | -216.09% | ― | -26.10% | 14.85% |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AVD | American Vanguard Corporation | 1.10 | -3.57 | -76.45% | |
| UAN | CVR Partners LP | 126.76 | 39.83 | 45.81% | |
| IPI | Intrepid Potash Inc | 31.58 | 5.30 | 20.17% | |
| BHST | Bioharvest Sciences, Inc. | 1.66 | -7.59 | -82.05% | |
| BIOX | Bioceres Crop Solutions | 0.21 | -1.65 | -88.82% |
American Vanguard Corporate Events
American Vanguard appoints new chief financial officer
PositiveOn October 1, 2026, American Vanguard’s board completed a planned leadership transition in its finance organization, appointing 43-year-old Matthew Horwath as Chief Financial Officer and moving long-serving CFO David Johnson to the role of Chie...
American Vanguard Reports Mixed Q2 2026 Results Amid Challenges
NegativeOn August 10, 2026, American Vanguard reported second-quarter and first-half 2026 results showing mostly flat sales but mixed profitability trends versus 2025, as it works through challenging global agricultural market conditions. Second-quarter net...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 17, 2026